Incentives and disincentives to drug innovation: evidence from recent literature

References

• Rose-Ackerman S. Altruism, nonprofits, and economic theory. J Econ Literature. 1996;34:701–728.
   Web of Science ®Google Scholar
• Lazear EP. Economic imperialism. Q J Econ. 2000;115:99–146.
   Web of Science ®Google Scholar
• Mwachofi A, Al-Assaf AF. Health care market deviations from the ideal market. Sultan Qaboos Univ Med J. 2011;11:328–337.
   PubMedGoogle Scholar
• Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;53:941–973.
   Web of Science ®Google Scholar
• Phelps CE. Health Economics. 3rd ed. Boston: Addison Wesley; 2003.
   Google Scholar
• 2019 annual meeting of the Allied Social Sciences Association (ASSA), Atlanta, Georgia, January 3–6, 2019.
   Google Scholar
• Culyer AJ. A Glossary of the more common terms encountered in health economics. In: Hersh-Cochran MS, Cochran KP, editors. Compendium of English language course syllabi and textbooks in health economics. Copenhagen: World Health Organization; 1989. pp. 215–234.
   Google Scholar
• Polyakova M, Bundorf K, Tai-Seale M. Delegating decision-making to the machine: Experimental evidence from health insurance. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Dranove D, Ody C, Starc A. A dose of managed care: Controlling drug spending in Medicaid. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Agha L, Zeltzer D. Drug diffusion through peer networks: The influence of industry payments. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA. Available from: https://en-econ.tau.ac.il/sites/economy_en.tau.ac.il/files/3-2018%20Leila%20Agha%20Dan%20Zeltzer.pdf.
   Google Scholar
• Cunningham C, Ederer F, Ma S. Killer acquisitions. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Hermosilla M. Reactive outsourcing of technological innovations. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Krieger JI, Li X, Thakor RT. Find and replace: R&D investment following the erosion of existing products. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Krieger J, Li D, Papanikolaou D. Missing novelty in drug development. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 5; Atlanta, GA.
   Google Scholar
• Fossett SJ, Wunnava PV. Active ingredients: Exploring the key factors affecting the rising cost of developing new drugs. Paper presented at the annual meeting of the Allied Social Sciences Association (ASSA); 2019, Jan 6; Atlanta, GA.
   Google Scholar
• Keehan SP, Stone DA, Poisal JA, et al. National health expenditure projections, 2016–25: price increases, aging push sector to 20 percent of economy. Health Aff (Millwood). 2017;36:553–563.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Morton FS, Boller LT. Enabling competition in pharmaceutical markets. Hutchins Center working paper #30, Yale School of Management, New Haven, CT; 2017. [Accessed February 23, 2019]. Available from: https://www.ftc.gov/es/system/files/documents/public_comments/2017/12/00508-142616.pdf.
   Google Scholar
• Mendoza RL. Merit goods at fifty: reexamining Musgrave’s theory in the context of health policy. Re Econ Bus Stud. 2011;4:275–284.
   Google Scholar
• Investopedia. What are barriers to entry for pharma companies? 2018. [Accessed February 23, 2019]. Available from: https://www.investopedia.com/ask/answers/052215/what-are-major-barriers-entry-new-companies-drugs-sector.asp.
   Google Scholar
• Mendoza RL. Information asymmetries and risk management in healthcare markets: the U.S. Affordable Care Act in retrospect. J Econ Issues. 2017;51:520–540.
   Web of Science ®Google Scholar
• Danzon PM. Health care industry. In: Henderson DR, editor. The Fortune encyclopedia of economics. New York: Warner Books; 1993. pp. 677–683.
   Google Scholar
• Burns L, Wharton School colleagues. The health care value chain: Producers, purchasers, and providers. Hoboken (NJ): Jossey-Bass/Wiley; 2002.
   Google Scholar
• Aitken M, Machin C, Troein P. Understanding the pharmaceutical value chain. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2014.
   Google Scholar
• The Health Strategies Consultancy LLC. Follow the pill: Understanding the U.S. commercial pharmaceutical supply chain. Menlo Park (CA): The Henry H. Kaiser Family Foundation; 2005.
   Google Scholar
• Olson L. How does the pharmaceutical supply chain work? 2018. [Accessed March 4, 2019]. Available from: https://www.datexcorp.com/how-does-the-pharmaceutical-supply-chain-work/
   Google Scholar
• Waning B, Maddix J, Soucy L. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyztan. BMC Health Serv Res. 2010;10:205.
   PubMed Web of Science ®Google Scholar
• Lindsley CW. New 2017 data and statistics for pharmaceutical products. ACS Chem Neurosci. 2018;9:1518–1519.
   PubMed Web of Science ®Google Scholar
• No author. Challenging the link between pharma innovation and US drug pricing. Pharmaceutical technology; May 12, 2017 [Accessed March 3, 2019]. Available from: https://www.pharmaceutical-technology.com/features/featurechallenging-the-link-between-pharma-innovation-and-us-drug-pricing-5813154/
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2017.
   Google Scholar
• Griffiths EA, Vadlamudi NK. Cadth’s $50,000 cost-effectiveness threshold: Fact or fiction? Value Health. 2016;19:A488–A489.
   Web of Science ®Google Scholar
• Kissick W. Medicine’s dilemmas: Infinite needs versus finite resources. New Haven and New London (CT): Yale University Press; 1994.
   Google Scholar